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Background: Deubiquitinases, such as CYLD, A20 and Cezanne, have emerged as negative regulators that balance
the strength and duration of NF-κB signaling through feedback mechanisms. However, how these serial feedback
loops are simultaneously disrupted in cancer remains unclear. The purpose of this study is to investigate the
correlation of Cezanne expression with clinicopathological/prognostic value in hepatocellular carcinoma (HCC).
Methods: The expression levels of Cezanne and matrix metallopeptidase 9 (MMP-9) were assessed by
immunohistochemistry in 230 HCC specimens. The correlation between expression of Cezanne and MMP-9,
clinicopathological/prognostic value in hepatocellular carcinoma was examined.
Results: Cezanne reduction in HCC was significantly associated with larger tumor, satellite nodule, vascular
invasion, TNM stage, BCLC stage and early recurrence. Kaplan-Meier analysis showed that Cezanne was a great
predictive factor for overall survival (OS) and time to recurrence (TTR). The expression of Cezanne was decreased
in TNM and BCLC stage-dependent manner. In addition, Cezanne reduction was associated with poor prognosis
in patients subgroups stratified by tumor size, tumor differentiation, TNM stage and BCLC stage. Moreover, Cezanne
was negatively associated with MMP-9 among 230 HCC samples. Patients who had Cezanne downregulation, in which
cancer cells showed high invasiveness, had shorter TTR and poor OS. Furthermore, the coindex of Cezanne and
preoperative serum AFP levels was significantly correlated with OS and TTR.
Conclusion: Cezanne has a pivotal role in tumor progression and prognosis, and may act as a potential prognostic
biomarker for survival in HCC patients.
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Hepatocellular carcinoma (HCC) is one of the most
common solid tumors and prevalent fatal cancers world-
wide, especially in East Asia and Sub-Saharan Africa
[1,2]. Surgery resection is the preferred curative method,
however, a high incidence of postoperative metastasis
and recurrence generates a leading challenge as this
cancer is most resistant to conventional systemic radio-
therapy and chemotherapy [3,4]. In addition, survival
may vary widely among HCC patients with the same* Correspondence: guorp@sysucc.org.cn
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unless otherwise stated.clinicopathologic features, which is most likely attribut-
able to the heterogeneity of the biological behaviour of
tumor cells [5,6]. Therefore, screening the biomarkers
for better valuation of recurrence and prognosis of HCC
can guide molecular targeting therapy for the improve-
ment of more effective treatments and inhibition of
metastasis.
The importance of understanding the molecular biology
of HCC has recently gained considerable attention, as mo-
lecular targeting therapy has shown encouraging results
for many malignancies [7,8]. The key signal transduction
pathways implicated in the pathogenesis of liver cancer in-
clude the PI3K/Akt/mTOR pathway [9], Wnt/β-catenin
signalling cascade [10], and the NF-κB signalling pathway
[11,12]. The NF-κB family of transcription factors has anThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics
Variable No. of patients (%)
No. of patients 230 (100)







AFP: Median [range], ng/mL 157.3 [0.6-121000]
GGT: Median [range], U/l 45.0 [3.5-655.5]

































Table 1 Patient characteristics (Continued)
Recurrence status
No 105 (45.6)
Early recurrence 85 (37.0)
Late recurrence 40 (17.4)
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thermore, NF-κB is increasingly recognized as a crucial
player in many steps of cancer initiation and progression
[13]. Studies in cultured cells have demonstrated that
NF-κB activity is down-regulated by overexpression of
ubiquitin-editing enzyme A20 [14].
Cezanne is a member of the A20 family of deubiqui-
tinating enzymes [15]. Similar to A20, Cezanne has
been shown to inhibit NF-κB pathway by deconjugat-
ing K63-polyubiquitin chains from RIP-1 and TRAF6
[15,16], which suggests that it may have roles in inhibition
of cancer progression. Cezanne is implicated in cancer
biology as a 93-kb sequence containing Cezanne was
shown to be duplicated in acute lymphoblastic leukemia
and Burkitt lymphoma [17]. However, the role of Cezanne
in prognosis of HCC patients has not been well clarified.
In this study, we explored the expression of Cezanne
in HCC tissues by immunohistochemistry (IHC). Correl-
ation of Cezanne with clinicopathological parameters and
prognosis of HCC patients were analysed. Moreover, it
has been known that MMP-9 is closely participated in
capsular infiltration and metastasis in HCC [18] and
serum AFP level is an unfavorable prognostic factor for
HCC patients [19]. Therefore, we also assessed the associ-
ation of Cezanne with MMP-9 protein and investigated
the prognostic value of Cezanne combined with serum
AFP level in HCC patients.
Patients and methods
Patients and specimens
The study was approved by the Institutional Review
Board and Human Ethics Committee of Sun Yat-Sen
University Cancer Center. Written consent for using the
samples for research purposes was obtained from all pa-
tients prior to surgery.
All hepatocellular carcinoma samples and adjacent
non-tumorous liver tissues were collected from 230 pa-
tients who had undergone curative resections from pri-
mary HCC between November 2007 and February 2009 at
the Department of Hepatobiliary Oncology, Sun Yat-sen
University (Guangzhou, China). The eligibility criteria of
the current study were as follows: (1) all the samples in-
cluding HCC and adjacent non-tumorous tissues were
histologically confirmed, (2) none of the patients had dis-
tant metastasis or received anticancer therapies before the
operation, (3) no serious complications or other malignant
diseases. The cases were selected consecutively on the
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The clinicopathological features were obtained from pa-
tients’ files (Table 1). Tumor stage was classified accord-
ing to the 7th Edition tumor-node-metastasis (TNM)
classification of the American Joint Committee on Can-
cer Staging and the Barcelona Clinic Liver Cancer
(BCLC) staging system. Overall survival (OS) was defined
as from the date of liver resection to the date of death or
last follow-up. Time to recurrence (TTR) was measured
from the date of surgery until the date of relapse, metasta-
sis, or last follow-up.
IHC staining
A total of 230 HCC tissues and their adjacent non-
tumorous samples were used in the IHC analysis.
Formalin-fixed, paraffin-embedded specimens from con-
senting patients were cut in 4 μm sections. After being
baked at 60°C for 2 h, the samples were deparaffinized
in xylene and rehydrated using a series of graded alcohols.
Then, the tissue slides were treated with 3% hydrogen per-
oxide in methanol for 10 min to exhaust endogenous per-
oxidase activity. The sections were microwaved antigen
retrieval in 0.01 M sodium citrate buffer (pH 6.0) for
30 min, and then preincubated in 10% normal goat serum
for 30 min to prevent nonspecific staining. The sections
were incubated with the Cezanne mouse monoclonal anti-
body (working dilution 1:200, Abcam, #ab118387, UK)
and MMP-9 rabbit polyclonal antibody (working dilution
1:200, Abcam, #ab38898, UK) overnight at 4°C. The
sections were treated with a non-biotin horseradish-
peroxidase detection system based on the manufacturer’s
instructions (DAKO, Glostrup, Denmark). Assessments of
the staining were scores by two experienced pathologistsFigure 1 Cezanne was significantly down-regulated in hepatocellular
expression in 230 paired HCC and adjacent non-tumorous tissues. In patient #
in adjacent non-tumorous tissue and HCC specimen. The upper right panel re
middle panel. In patient #2, the lower left panel represents high Cezanne exp
represents low Cezanne expression in HCC. Lower right panel represents mag
The full line and dotted line scale bar represents 50 μm and 10 μm, respective
non-tumorous specimens. Statistical analysis was performed by Paired-Sampleblinded to the patients’ identity and clinical status. In dis-
crepant cases, a pathologist reviewed the cases and
reached the consensus.
Both the extent and intensity of immunostaining were
taken into consideration when analyzing the data. The
intensity of staining was scored from 0 to 3, and the ex-
tent of staining was scored from 0% to 100%. The final
quantitation of each staining was obtained by multiply-
ing the two scores. Cezanne expression was classified as
high expression if the score was higher than the median
score of 1.3, if the score was 1.3 or less, the case was
classified as low expression. MMP-9 expression was con-
sidered high if the score was higher than 1.4.
Follow-up
The last follow-up was on 30 February 2014. In all the
HCC patients (26 females and 204 males), the median
follow-up period was 44.5 months, ranging from 3 to
73 months. Recurrence was confirmed by serum α-
fetoprotein (AFP) level, abdominal ultrasonography every
2 months, and computed tomography or magnetic reson-
ance imaging or positron emission tomography every
6 months after hepatectomy. The main causes of death
were HCC recurrence or complicated cirrhosis of the
liver. During the course of follow-up, 125 of 230 HCC
patients (54.3%) were found with recurrence and 104
patients (45.2%) died of cancer-related causes. One hun-
dred and twenty-six patients were still alive at the time of
the last follow-up report.
Statistical analysis
The SPSS software package (version 16.0; Chicago, IL,
USA) was used for the statistical analysis. The chi-squarecarcinoma (HCC). (a) Immunohistochemistry (IHC) assays of Cezanne
1, the upper left and middle panel represents high Cezanne expression
presents magnified pictures of boxed area in the corresponding upper
ression in adjacent non-tumorous tissue, while the lower middle panel
nified pictures of boxed area in the corresponding lower middle panel.
. (b) Cezanne expression levels were compared with HCC and adjacent
s t-test.




Cezanne expression (%) P-value
Low High
Gender
Female 26 10 (38.5%) 16 (61.5%) 0.103
Male 204 113 (55.4%) 91 (44.6%)
Age (years)
≤50 118 62 (52.5%) 56 (47.5%) 0.826
>50 112 61 (54.5%) 52 (45.5%)
AFP (μg/l)
≤20 82 44 (53.7%) 38 (46.3%) 0.967
>20 148 79 (53.4%) 69 (46.6%)
HBsAg
Negative 15 9 (60.0%) 6 (40.0%) 0.600
Positive 215 114 (53.0%) 101 (47.0%)
GGT (U/l)
≤50 122 58 (47.5%) 64 (52.5%) 0.055
>50 108 65 (60.2%) 43 (39.8%)
Liver cirrhosis
No 50 26 (52.0%) 24 (48.0%) 0.813
Yes 180 97 (53.9%) 83 (46.1%)
Tumor size (cm)
≤5 132 58 (43.9%) 74 (56.1%) 0.001
>5 98 65 (66.3%) 33 (33.7%)
Tumor number*
Single 213 113 (53.1%) 100 (46.9%) 0.646
Multiple 17 10 (58.8%) 7 (41.2%)
Satellite nodule
No 199 98 (49.2%) 101 (50.8%) 0.001
Yes 31 25 (80.6%) 6 (19.4%)
Tumor capsule
No/incomplete 141 77 (54.6%) 64 (45.4%) 0.665
Complete 89 46 (51.7%) 43 (48.3%)
Tumor differentiation
I-II 157 88 (56.1%) 69 (43.9%) 0.251
III-IV 73 35 (47.9%) 38 (52.1%)
Vascular invasion
No 207 105 (50.7%) 102 (49.3%) 0.012
Yes 23 18 (78.3%) 5 (21.7%)
TNM stage
I 178 88 (49.4%) 90 (50.6%) 0.020
II 11 5 (45.5%) 6 (54.5%)
III 41 30 (73.2%) 11 (26.8%)
Table 2 Correlation of Cezanne protein expression with
clinicopathological parameters (Continued)
BCLC stage
0 20 4 (20.0%) 16 (80.0%) 0.001
A 106 52 (49.1%) 54 (50.9%)
B 80 49 (61.3%) 31 (38.7%)
C 24 18 (75.0%) 6 (25.0%)
Early recurrence
No 145 56 (38.6%) 89 (61.4%) <0.001
Yes 85 67 (78.8%) 18 (21.2%)
MMP-9 expression
Low 118 51 (43.2%) 67 (56.8%) 0.001
High 112 72 (64.3%) 40 (35.7%)
*Tumor number indicates number of primary tumor mass detected at the time
of surgical operation.
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with clinicopathological features. The Student’s t-test was
used for comparisons. Pearson χ2 test was applied to
analyze the correlation of Cezanne with MMP-9 staining
scores. Survival curves were generated using the Kaplan-
Meier method, and differences between curves were esti-
mated by the log-rank test. All P values were two-sided
and P values less than 0.05 was considered to be statisti-
cally significant.Results
Cezanne expression in HCC
To illuminate the biological significance of Cezanne in
HCC, we investigated the immunohistochemical expression
of Cezanne in 230 HCC specimens (tumor and matched
adjacent non-tumorous tissues). We observed that Cezanne
was primarily localized in the nucleus (Figure 1a). We de-
tected low expression of Cezanne in 123/230 (53.5%) of pri-
mary HCC specimens, compared with 92/230 (40.0%) in
adjacent non-tumorous tissues (P = 0.045; Figure 1b). These
data indicated that Cezanne expression was significantly
lower in HCC tissues than that in adjacent non-tumorous
tissues.Correlation of Cezanne with clinicopathological variables
To verify the functions of Cezanne in HCC, we corre-
lated Cezanne status in 230 HCC samples with 15 widely
recognized clinicopathological features (Table 2). Our re-
sults revealed that the low expression of Cezanne in
HCC was associated with larger tumor (>5 cm in diam-
eter) (P = 0.001), satellite nodule (P = 0.001), vascular in-
vasion (P = 0.012), TNM stage (P = 0.020), BCLC stage
(P = 0.001) and early recurrence (P < 0.001) (Table 2). In
contrast, Cezanne expression displayed no correlation with
gender, age, AFP, HBsAg, gamma-glutamyltransferase
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and tumor differentiation (all P > 0.05).
Prognostic value of Cezanne
To further confirm the effect of Cezanne status on OS
and TTR in HCC, we performed univariate analysis of
traditional clinicopathologic parameters for prognosis.
The results revealed that low expression of Cezanne
(P < 0.001), high AFP level (P = 0.016), high GGT level
(P = 0.001), liver cirrhosis (P = 0.006), larger tumor size
(P < 0.001) and vascular invasion (P < 0.001) were un-
favourable predictors for OS of HCC patients. In addition,
Kaplan-Meier analysis demonstrated that low Cezanne ex-
pression (P < 0.001), high AFP level (P = 0.049), high GGT
level (P = 0.006), liver cirrhosis (P = 0.012), larger tumor
size (P < 0.001), multiple tumor number (P = 0.025), satel-
lite nodule (P = 0.009) and vascular invasion (P < 0.001)
were significantly associated with shorter TTR in HCC pa-
tients (Table 3). Moreover, we assessed whether Cezanne
could be an independent predictors for OS and TTR in
HCC patients. A multivariate Cox model adjusted for
AFP, GGT, liver cirrhosis, tumor size, tumor number, sat-
ellite nodule, vascular invasion and Cezanne expression
was performed. Our data revealed that the Cezanne status
was an independent negative prognostic factor for OS
(HR = 0.352, 95% CI = 0.226-0.546, P < 0.001) and TTR
(HR = 0.354, 95% CI = 0.237-0.528, P < 0.001) in HCC pa-
tients (Table 3).
Kaplan-Meier analysis revealed that OS and TTR were
significantly different in 230 HCC patients based on the




Gender (Female vs. Male) NS NS
Age, years (≤50 vs. > 50) NS NS
AFP (ng/mL) (≤20 vs. > 20) 0.016 NS
HBsAg (Negative vs. Positive) NS NS
GGT (U/l) (≤50 vs. > 50) 0.001 NS
Liver cirrhosis (No vs. Yes) 0.006 0.008
Tumor size (cm) (≤5 vs. > 5) <0.001 0.032
Tumor number (Single vs. Multiple) NS NS
Satellite nodule (No vs. Yes) NS NS
Tumor capsule (No/incomplete vs. Complete) NS NS
Tumor differentiation (I-II vs. III-IV) NS NS
Vascular invasion (No vs. Yes) <0.001 <0.001
Cezanne (Low versus High) <0.001 <0.001
*TNM stage and BCLC stage was combined with several clinical indexes such as tum
BCLC stage into multiple analysis with these indexes to avoid any bias in analysis.
GGT gamma-glutamyltransferase, AFP α-fetoprotein, OS overall survival, TTR time tomedian of OS was 44.5 months, while the median of
TTR was 34.0 months. In addition, the median of OS
times in Cezanne down-regulation (n = 123) and Cezanne
up-regulation (n = 107) HCC patients subgroups were
31.0 months and 57.0 months, while the median of the
TTR were 18.0 months and 55.0 months. Furthermore,
the 5-year OS and TTR rates of the Cezanne down-
regulation group were 37.5% and 26.6%, which were sig-
nificantly lower than that of the Cezanne up-regulation
group (71.6% and 61.4%) (Figure 2a). Moreover, the ex-
pression levels of Cezanne in tumors decreased in TNM
and BCLC stage-dependent manner, and they were signifi-
cantly lower in TNM stage III and BCLC stage C tumors
than in TNM stage I and BCLC stage 0 tumors (Figure 3).
To further evaluate the prognostic value of Cezanne
in different subgroups, patients were stratified accord-
ing to tumor size (Figure 2b, c), tumor differentiation
(Figure 2d, e), TNM stage (Figure 2f, g) and BCLC
stage (Figure 2h, i). The Cezanne reduction maintained
its prognostic value in predicting shorter OS and TTR
in all of these subgroups. Therefore, it suggests that
Cezanne may serve as a potential prognostic biomarker
for HCC patients in different risk groups.
Cezanne down-regulation predicts poor prognosis
independent of tumor invasiveness
To better understand the clinical significance of Cezanne
on progression in HCC, we evaluated the correlation of
Cezanne and MMP-9 expression in HCC patients.
The positive rates of Cezanne were only 21.7% and
21.2% in the vascular invasion group and early recurrenceciated with survival and recurrence in HCC patients
TTR
e Univariate Multivariate






2.216 1.232-3.985 0.012 0.017 1.865 1.115-3.117





2.941 1.706-5.072 <0.001 <0.001 2.471 1.475-4.138
0.352 0.226-0.546 <0.001 <0.001 0.354 0.237-0.528
or size, number and tumor thrombus; we did not enter the TNM stage and
recurrence, NS not significant, HR hazard ratio, CI confidential interval.
Figure 2 Overall survival and time to recurrence are shown for patients with HCC. All patients were stratified according to tumor size,
tumor differentiation, TNM classification and BCLC stage. Kaplan-Meier survival estimates and log-rank tests were used to analyze the prognostic
significance of Cezanne expression in all patients (a) and each subgroup (b-i).
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Figure 3 Comparsion of Cezanne expression by TNM stage and BCLC stage. Cezanne expression is markedly decreased as tumors progress
in TNM stage (a) and BCLC stage (b). Statistical analysis was performed by Student’s t-test.
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vascular invasion and early recurrence groups (P = 0.012
and P < 0.001, respectively) (Table 2). In addition, Sixty-
seven of 118 (56.8%) patients with low MMP-9 expression
had high Cezanne expression, while 72 of 112 patients
(64.3%) with high MMP-9 expression had low Cezanne
expression (P = 0.001, Table 2). Moreover, the relationship
of Cezanne and MMP-9 was further confirmed by IHC
assays in serial sections of HCC tissues (Figure 4a). The
results showed that Cezanne was negatively associated
with MMP-9 in 230 HCC samples (r = −0.377, P < 0.001,
Figure 4b).
We further investigated the impact of tumor invasive-
ness on the prognosis of Cezanne expression in HCC by
using MMP-9 marker as an indicator for invasive poten-
tial of tumor cells. The HCC patients were classified into
either low invasiveness group (low MMP-9 expression;
n = 118) or high invasiveness group (high MMP-9 expres-
sion; n = 112) based on the MMP-9 expression index.
Kaplan-Meier survival curves were then plotted to deter-
mine the correlation of Cezanne expression and survivalFigure 4 Cezanne and MMP-9 levels correlated in 230 HCC tissues. (a
with antibodies against Cezanne and MMP-9. In case #1, high expression o
In case #2, low expression of Cezanne was accompanied by elevated M
analysis between Cezanne and MMP-9 expression in 230 HCC patients b
MMP-9 expression.(Figure 5). In the low invasiveness group, Cezanne down-
regulation was correlated with poor OS (P = 0.005) and
shorter TTR (P = 0.003) compared with the survival in
Cezanne up-regulation patients (Figure 5a). In the high
tumor invasiveness group (Figure 5b), patients with
Cezanne down-regulation were prone to death (P < 0.001)
and relapse (P < 0.001). Therefore, the expression of
Cezanne appears to be a strong postoperative prognostic
parameter for patients with HCC independent of tumor
invasiveness.
Prognostic significance of Cezanne combined with serum
AFP level on HCC recurrence and survival
It has been known that serum AFP levels are an unfavor-
able prognostic factor for HCC patients [19]. Univariate
analysis indicated that preoperative serum AFP level
above 20 ng/mL was significantly associated with shorter
OS (P = 0.016) and TTR (P = 0.049) (Table 3). Therefore,
we evaluated the prognostic value of Cezanne expression
with serum AFP levels for recurrence and survival of
HCC patients. Based on Cezanne expression and serum) Serial sections of human HCC tissue were subjected to IHC staining
f Cezanne in HCC tissues was accompanied by the absence of MMP-9.
MP-9. The scale bar represents 50 μm. (b) Spearman correlation
y IHC assays. Cezanne expression was negatively correlated with
Figure 5 Overall survival and time to recurrence are shown for
patients with low tumor invasiveness (a) and high tumor
invasiveness (b). Kaplan-Meier survival estimates and log-rank tests
were used to analyze the association between Cezanne expression
and overall survival or time to recurrence in patients with low
invasiveness (low MMP-9; n = 118) or high invasiveness (high
MMP-9; n = 112).
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groups with different recurrent risks and prognosis:
group I, Cezanne (−) and AFP > 20 ng/mL, poor progno-
sis and high-risk of recurrence; group II with Cezanne
(−) and AFP ≤ 20 ng/mL, or Cezanne (+) and AFP >
20 ng/mL, intermediate prognosis and intermediate-risk
of recurrence; group III with Cezanne (+) and AFP ≤
20 ng/mL good prognosis and low-risk of recurrence
(Figure 6). Multivariate analysis further demonstrated
that the coindex of Cezanne/AFP was an independent
prognostic factor for OS (HR = 0.475, 95% CI = 0.348-
0.648, P < 0.001) and TTR (HR = 0.515, 95% CI = 0.389-
0.681, P < 0.001) (Table 4).Figure 6 Kaplan-Meier survival curves according to Cezanne expressi
survival (log-rank P < 0.001). (b) Time to recurrence (log-rank P < 0.001).Disussion
The development of hepatocellular carcinoma (HCC) is
closely associated with chronic inflammation caused by
viral infection, alcohol consumption, or hepatic metabolic
disorders. Evidences have suggested that NF-κB signaling
pathway plays an important role in various liver disease
and HCC. Persistent NF-κB activation appears to have a
central role in the inflammation-fibrosis-cancer axis [20].
NF-κB has been related to initiation, promotion, and pro-
gression of HCC [21,22]. Inhibition of NF-κB activity sig-
nificantly reduced proliferation and invasion of HCC cells
as well as downregulated the expression of invasion-
related molecules including MMP-9 [23], NF-κB could
play an important role in MMP-9 regulation [24,25].
Cezanne expression was shown to be rapidly induced by
NF-κB signaling stimulated by TNF-α in a negative feed-
back manner [16]. In addition, Cezanne negatively modu-
lates NF-κB signaling pathway which has an important
role in liver pathology [16,20]. In this study, the expression
of Cezanne was explored in 230 HCC tissues by IHC.
We found that Cezanne was down-regulated in HCC
tissues compared with adjacent non-tumorous tissues.
In addition, Cezanne was significantly associated with
tumor size, satellite nodule, vascular invasion, TNM
stage, BCLC stage and early recurrence. Moreover, the
Kaplan-Meier survival analysis showed that the OS and
TTR of HCC patients with low Cezanne expression
were shorter than those with high Cezanne expression.
The prognostic value of Cezanne in different subgroups
based on tumor size, tumor differentiation, TNM stage
and BCLC stage was also estimated, which appears that
Cezanne may serve as a powerful prognostic factor for
patients with HCC in different risk groups. According
to the results of multivariate analysis, we found that
Cezanne down-regulation was an independent predictor
for poor OS as well as TTR in HCC. Furthermore, the
expression levels of Cezanne were significantly lower in
TNM stage III and BCLC stage C tumors than in TNM
stage I and BCLC stage 0 tumors. The results indicate
that Cezanne has a pivotal role in tumor prognosis,on combined with serum AFP level in 230 HCC patients. (a) Overall
Table 4 Univariate and multivariate analysis of coindex of Cezanne/AFP associated with survival and recurrence in HCC
patients
Variables OS TTR
Univariate Multivariate Univariate Multivariate
P-value P-value HR 95% CI P-value P-value HR 95% CI
Gender (Female vs. Male) NS NS NS NS
Age, years (≤50 vs. > 50) NS NS NS NS
HBsAg (Negative vs. Positive) NS NS NS NS
GGT (U/l) (≤50 vs. > 50) 0.001 NS 0.006 NS
Liver cirrhosis (No vs. Yes) 0.006 0.010 2.169 1.207-3.897 0.012 0.030 1.756 1.055-2.923
Tumor size (cm) (≤5 vs. > 5) <0.001 0.037 1.589 1.027-2.458 <0.001 0.007 1.785 1.175-2.710
Tumor number (Single vs. Multiple) NS NS 0.025 NS
Satellite nodule (No vs. Yes) NS NS 0.009 NS
Tumor capsule (No/incomplete vs. Complete) NS NS NS NS
Tumor differentiation (I-II vs. III-IV) NS NS NS NS
Vascular invasion (No vs. Yes) <0.001 <0.001 3.027 1.755-5.221 <0.001 <0.001 2.615 1.559-4.386
Coindex of Cezanne/AFP* <0.001 <0.001 0.475 0.348-0.648 <0.001 <0.001 0.515 0.389-0.681
*Coindex of Cezanne/AFP was combined with Cezanne and AFP, therefore, we did not enter the Cezanne and AFP into univariate and multiple analysis with these
indexes to avoid any bias in analysis.
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biomarker of HCC. Our findings had similar results
with previous study. Kanki et al. [26] found that low
OTUD7B mRNA expression was correlated with poor
prognosis for HCC patients. Moreover, OTUD7B nega-
tively regulated NF-κB signaling pathway, which may be
an effective target for antitumor therapy for HCC. Song
et al. [27] reported that Cezanne is downregulated in
gliomas and correlates inversely with the glioma WHO
grading and positively with patients’ survival time. In
addition, Cezanne could be used as a tumor suppressor
to inhibit the progression of glioma. Our findings and
previous observations strongly implicate that Cezanne
reduction is involved in the tumor progression and may
serve as a prognostic factor for HCC patients.
The degradation of extracellular matrix (ECM) is a
signal for the beginning of invasion and metastasis, and
matrix metalloproteases are pivotal enzymes that par-
ticipate in degradation of ECM during invasion and
metastasis [28]. MMP-9 was shown to modulate the
bioavailability of growth factors and to disrupt cell-cell
contacts, dramatically affecting cell proliferation and
survival [29]. Arii et al. [18] reported that the expression
of MMP-9 mRNA in HCC with capsular infiltration was
significantly higher than in HCC without capsular infiltra-
tion. In addition, MMP-9 immunoreactivity was the most
intense in the HCC cells, particularly in those cells in the
marginal areas of the tumorous tissues. MMP-9 is an in-
dependent predictor of tumor recurrence and survival
in HCC patients [30]. Our results demonstrated that
Cezanne was negatively correlated with MMP-9 protein
expression. Moreover, the expression of Cezanne waslow in patients with vascular invasion and early recur-
rence (Table 2), the tumor cells with Cezanne overex-
pression revealed low invasiveness, and low Cezanne
expression was a strong predictor of poor prognosis in
patients with HCC independent of tumor cell invasive-
ness (Figure 5). Collectively, Cezanne status in HCC
inhibiting tumor progression indicates that Cezanne can
be a potential target in cancer therapy.
AFP is a useful tumor-associated antigen for the diag-
nosis and predicted prognosis of HCC and monitoring
metastasis and tumor recurrence in HCC patients with
high AFP after hepatectomy [31,32]. However, it is hard
to predict the prognosis and metastatic recurrence of
normal AFP HCC patients after curative resection. To
investigate whether the prognostic value of Cezanne
combined with serum AFP level was superior to AFP
alone, we divided the HCC patients into three groups ac-
cording to Cezanne expression and serum AFP level and
found that combination of Cezanne and serum AFP level
could be used for predicting the risk of tumor recurrence
and survival of patients. HCC patients can be classified to
different subgroups with different risks of tumor recur-
rence and prognosis according to Cezanne expression in
HCC tissue and preoperative AFP level. Therefore, ana-
lysis of Cezanne expression and serum AFP level may help
determine whether adjuvant therapy is required after
resection.
Conclusion
In summary, our results revealed that Cezanne may have
a pivotal role in tumor invasion and prognosis, and can
act as a feasible biomarker for prognostic prediction in
Wang et al. Journal of Translational Medicine  (2015) 13:41 Page 10 of 10HCC. Moreover, the combination of Cezanne with serum
AFP level may help to identify the high-risk HCC patients
after curative resection and thus aid to select appropriate
therapies. It also requires further studies to clarify the
underlying biology of Cezanne in the development of
HCC.
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